An FDA panel just backed six peptides. Did that make them legal?
No.On 23–24 July 2026 an FDA advisory committee voted to recommend six of seven peptides for the 503A bulks list — overruling FDA’s own scientists, who had recommended against all seven. Those votes are non-binding recommendations. We checked the bulks list on 29 July 2026, six days after the vote: it is still dated 14 May 2026, and none of the seven appears in it. Nothing is on the list. Nothing became compoundable.
This is the second time in four months the same mistake is being made in opposite directions. In April, twelve peptides left Category 2 because the nominators withdrew their nominations, and that was reported as legalisation. It was not. Now a favourable advisory vote is being reported as legalisation. It is not that either. Both readings skip the same step: a recommendation is not a rule.FDA says so itself — “Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so.”
What Category 2 actually contains
As of the list updated 14 May 2026, exactly six substances: cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate (MK-677), kisspeptin-10, and quinacrine hydrochloride for intrauterine administration.
So the popular summary is wrong in both directions at once. It announces a freedom that did not arrive, and it misses the two things that actually are flagged — both of which are sold throughout this market.
Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act — FDA, 14 May 2026
44 peptides, two questions, no guessing
For each compound we ask two questions separately, because conflating them is how this category goes wrong: what is its legal status, and what does the evidence actually show? A substance can be flagged for safety and still have real clinical trials behind it. Another can have strong evidence and no approval at all. Every answer links to the primary document it came from, and the date we last checked it.
How the committee voted, and what each peptide’s status actually is
The Pharmacy Compounding Advisory Committee met on 23–24 July 2026. FDA staff briefing documents — which we read end to end — recommended against all seven. The committee agreed with its staff on exactly one.
| Peptide | Committee vote | On the bulks list? | Evidence |
|---|---|---|---|
| BPC-157 | Recommended (8-6, one abstention) | No | Promising but unproven |
| KPV | Recommended (8-6, one abstention) | No | Animal or in-vitro only |
| TB-500 | Recommended (8-6, one abstention) | No | No credible evidence |
| MOTS-c | Recommended (7-5, two abstentions) | No | Animal or in-vitro only |
| Semax | Recommended (8-5, one abstention) | No | Animal or in-vitro only |
| Epitalon | Recommended (7-5, one abstention) | No | Promising but unproven |
| Emideltide (DSIP) | Not recommended (6-7, one abstention) | No | Promising but unproven |
Every entry in the third column is “No”, including the six the committee recommended. That is the whole point: a recommendation is a recommendation. Adding a substance to the list requires separate FDA action, and as of 29 July 2026 none has been taken.
Sourcing note: the vote tallies come from news reporting — ABC News and others — because FDA had not published minutes or a transcript as of 29 July 2026. The bulks-list column is from the primary document. We will replace the tallies with FDA’s own record when it publishes. Some coverage reported “four peptides” rather than six of seven, which appears to count only the first day.
Why this site exists
Most of what is written about peptides is quoting something else. We read the primary documents and tell you what they say — including when the answer is that nobody knows.
We carry no advertising, accept no sponsorship, sell no products, and earn no commission on anything we write about. That is not modesty — it is the only arrangement under which the rest of this site can be honest. Most of what is true about most peptides is unflattering to the people selling them: no human data, a failed trial, an FDA recommendation against approval. A site funded by that industry cannot print that.
We also don’t publish dosing, for any compound, including approved ones. It is the most-wanted content in this category and we are leaving it on the table on purpose. Here is the whole policy, including how we verify things and what we refuse.
Common questions
- Did the FDA panel's July 2026 vote make BPC-157 legal?
- No. On 23 July 2026 an FDA advisory committee voted 8-6 with one abstention to recommend adding BPC-157 to the 503A bulks list, going against FDA's own staff. That recommendation is non-binding and FDA has not acted on it. Checked on 29 July 2026, six days after the vote, the 503A bulks list is still dated 14 May 2026 and BPC-157 appears nowhere in it. Nothing about its legal status has changed: it is not on the list and it is not compoundable.
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act — FDA, 14 May 2026
- What did the FDA advisory committee decide about peptides in July 2026?
- Meeting on 23-24 July 2026, the Pharmacy Compounding Advisory Committee voted to recommend six of seven peptides for the 503A bulks list — BPC-157, TB-500, KPV, MOTS-c, semax and epitalon — and voted against only emideltide (DSIP). FDA's own briefing documents had recommended against all seven, so the committee overruled its staff six times out of seven. The recommendations are advisory only; adding a substance to the list requires separate FDA action, which has not happened.
- FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list (Sony Salzman and Mary Kekatos) — ABC News, 23 July 2026
- Is an FDA advisory committee recommendation the same as FDA approval?
- No. In FDA's own words: “Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so.” A favourable committee vote is a recommendation about what FDA should consider, not a change in what is permitted. Until FDA itself acts and the bulks list changes, the legal status of a substance is whatever the list says.
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee — FDA, 23 July 2026
- Which peptides are in FDA's Category 2 for significant safety risks?
- As of the list updated 14 May 2026, Category 2 contains exactly six substances: cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate (MK-677), kisspeptin-10, and quinacrine hydrochloride for intrauterine administration. BPC-157, TB-500, CJC-1295, ipamorelin, MOTS-c, semax and epitalon are not among them — they appear nowhere in the document at all.
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act — FDA, 14 May 2026